JP2000514060A5 - - Google Patents

Download PDF

Info

Publication number
JP2000514060A5
JP2000514060A5 JP1998504196A JP50419698A JP2000514060A5 JP 2000514060 A5 JP2000514060 A5 JP 2000514060A5 JP 1998504196 A JP1998504196 A JP 1998504196A JP 50419698 A JP50419698 A JP 50419698A JP 2000514060 A5 JP2000514060 A5 JP 2000514060A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1998504196A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000514060A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/010696 external-priority patent/WO1998000412A1/en
Publication of JP2000514060A publication Critical patent/JP2000514060A/ja
Publication of JP2000514060A5 publication Critical patent/JP2000514060A5/ja
Ceased legal-status Critical Current

Links

JP10504196A 1996-07-01 1997-06-26 ムスカリン様アンタゴニスト Ceased JP2000514060A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67439196A 1996-07-01 1996-07-01
US08/674,391 1996-07-01
PCT/US1997/010696 WO1998000412A1 (en) 1996-07-01 1997-06-26 Muscarinic antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008194199A Division JP2009040778A (ja) 1996-07-01 2008-07-28 ムスカリン様アンタゴニスト

Publications (2)

Publication Number Publication Date
JP2000514060A JP2000514060A (ja) 2000-10-24
JP2000514060A5 true JP2000514060A5 (enExample) 2005-03-10

Family

ID=24706404

Family Applications (2)

Application Number Title Priority Date Filing Date
JP10504196A Ceased JP2000514060A (ja) 1996-07-01 1997-06-26 ムスカリン様アンタゴニスト
JP2008194199A Pending JP2009040778A (ja) 1996-07-01 2008-07-28 ムスカリン様アンタゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008194199A Pending JP2009040778A (ja) 1996-07-01 2008-07-28 ムスカリン様アンタゴニスト

Country Status (12)

Country Link
EP (1) EP0912534B1 (enExample)
JP (2) JP2000514060A (enExample)
KR (1) KR20000022380A (enExample)
AT (1) ATE224884T1 (enExample)
AU (1) AU717431B2 (enExample)
CA (1) CA2258044C (enExample)
DE (1) DE69715865T2 (enExample)
ES (1) ES2179353T3 (enExample)
HU (1) HUP9904167A3 (enExample)
IL (1) IL127858A0 (enExample)
NZ (1) NZ333322A (enExample)
WO (1) WO1998000412A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726736D0 (en) 1997-12-18 1998-02-18 Zeneca Ltd Chemical compounds
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
GB9914015D0 (en) * 1999-06-17 1999-08-18 Zeneca Ltd Chemical compounds
JP2002533447A (ja) * 1998-12-24 2002-10-08 アストラゼネカ・アクチエボラーグ 神経疾患の治療に有用な1,4−ジアザシクロヘプタン誘導体
GB9900078D0 (en) * 1999-01-05 1999-02-24 Zeneca Ltd Chemical compounds
GB9914024D0 (en) * 1999-06-17 1999-08-18 Zeneca Ltd Chemical compounds
GB9914022D0 (en) * 1999-06-17 1999-08-18 Zeneca Ltd Chemical compounds
GB9914025D0 (en) * 1999-06-17 1999-08-18 Zeneca Ltd Chemical compounds
US7067539B2 (en) * 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
CN100358870C (zh) * 2001-12-03 2008-01-02 弗·哈夫曼-拉罗切有限公司 作为毒蕈碱受体拮抗剂的氨基四氢萘衍生物
CN100349862C (zh) * 2002-11-25 2007-11-21 先灵公司 大麻素受体配体
WO2005037830A1 (en) 2003-10-10 2005-04-28 Wyeth Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands
EA015517B1 (ru) 2004-04-13 2011-08-30 Инсайт Корпорейшн Производные пиперазинилпиперидина в качестве антагонистов хемокинового рецептора
US7378415B2 (en) 2004-09-30 2008-05-27 Roche Palo Alto Llc Benzoxazine and quinoxaline derivatives and uses thereof
KR100899061B1 (ko) * 2004-12-21 2009-05-25 에프. 호프만-라 로슈 아게 테트랄린 및 인단 유도체 및 이의 용도
NZ560666A (en) * 2005-03-29 2010-01-29 Newron Pharm Spa Substituted aminoalkyl- and amidoalkyl-benzopyran derivatives
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
RU2008115032A (ru) 2005-11-03 2009-12-10 Ф. Хоффманн-Ля Рош Аг (Ch) Арилсульфонилхроманы в качестве ингибиторов 5-нт6
EP2041079A1 (en) 2006-06-20 2009-04-01 F. Hoffmann-Roche AG Arylsulfonyl naphthalene derivatives and uses thereof
AU2007263084A1 (en) 2006-06-20 2007-12-27 F. Hoffmann-La Roche Ag Tetralin and indane derivatives and uses thereof
CA2655524A1 (en) 2006-06-20 2007-12-27 F. Hoffman-La Roche Ag Arylsulfonamidyl tetralin derivatives and uses thereof
WO2010081851A1 (en) 2009-01-14 2010-07-22 Genoscience Pharma Piperidin-4-ylpiperazine compounds for the treatment of hcv infection
WO2011101774A1 (en) 2010-02-16 2011-08-25 Pfizer Inc. (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors
WO2017015349A1 (en) * 2015-07-20 2017-01-26 Chase Pharmaceuticals Corporation Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders
SG10202007787RA (en) * 2015-09-28 2020-09-29 Genentech Inc Therapeutic compounds and methods of use thereof
KR20240035820A (ko) 2021-07-09 2024-03-18 플렉시움 인코포레이티드 Ikzf2를 조절하는 아릴 화합물 및 약학 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD113545A5 (enExample) * 1973-03-30 1975-06-12
DE3064285D1 (en) * 1979-09-28 1983-08-25 Beecham Group Plc Chromanol derivatives, a process for their preparation and a pharmaceutical composition comprising them
PT89205B (pt) * 1987-12-14 1993-06-30 Beecham Group Plc Processo para a preparacao de derivados de indano
DK286990D0 (da) * 1990-12-04 1990-12-04 Lundbeck & Co As H Indanderivater
ES2164054T3 (es) * 1991-11-05 2002-02-16 Smithkline Beecham Corp Antagonistas de receptores de endotelina.
WO1994012493A1 (en) * 1992-11-25 1994-06-09 Sandoz, Ltd. 2,2-dialkyl- and 2,2-dialkyl-3,4-dihydro-3-hydroxy-2h-1-benzopyr ans, their use as pharmaceuticals

Similar Documents

Publication Publication Date Title
JP2000502280A5 (enExample)
JP2000501771A5 (enExample)
JP2000513471A5 (enExample)
JP2001500134A5 (enExample)
JP2001506223A5 (enExample)
JP2001501350A5 (enExample)
JP2000502472A5 (enExample)
JP2000501825A5 (enExample)
JP2000501338A5 (enExample)
JP2000502425A5 (enExample)
JP2000502568A5 (enExample)
JP2000501774A5 (enExample)
JP2000502570A5 (enExample)
JP2001502421A5 (enExample)
JP2000501876A5 (enExample)
JP2001502658A5 (enExample)
JP2000501744A5 (enExample)
JP2000502316A5 (enExample)
JP2000503458A5 (enExample)
JP2000502714A5 (enExample)
JP2001502534A5 (enExample)
JP2000514060A5 (enExample)
JP2000501569A5 (enExample)
JP2000500318A5 (enExample)
JP2000516572A5 (enExample)